New Drug Application Filed for Vandetanib in Second-Line NSCLC

Article

AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.

AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
First Patient Dosed in Trial for uniQure’s SOD1-ALS Gene Therapy AMT-162

First Patient Dosed in Trial for uniQure’s SOD1-ALS Gene Therapy AMT-162

Noah Stansfield
October 17th 2024
Article

The phase 1/2 EPISOD1 study, which is taking place in the US, will provide participants with a short immunosuppression regimen before administration of the gene therapy.

Adicet's T-Cell Therapy ADI-100 Snags Clearance for Evaluation in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet's T-Cell Therapy ADI-100 Snags Clearance for Evaluation in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Noah Stansfield
October 17th 2024
Article

Originally, the phase 1 clinical trial was only cleared for the recruitment of patients with lupus nephritis, but IND amendments have added more eligible indications.

Wave Life Sciences Achieves RNA Editing in Trial for WVE-006 in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Achieves RNA Editing in Trial for WVE-006 in Alpha-1 Antitrypsin Deficiency

Noah Stansfield
October 17th 2024
Article

According to the company, this is the first time therapeutic RNA editing has been clinically demonstrated in humans.

Around the Helix: Cell and Gene Therapy Company Updates – October 16, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 16, 2024

Noah Stansfield
October 16th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Beacon Therapeutics’ XLRP Gene Therapy AGTC-501 Continues to Show Promise in Long-Term Data From SKYLINE Trial

Beacon Therapeutics’ XLRP Gene Therapy AGTC-501 Continues to Show Promise in Long-Term Data From SKYLINE Trial

Noah Stansfield
October 16th 2024
Article

Among 7 patients’ eyes that were treated with the study’s high dose, the response rate was 57% (4/7 eyes).

Hematological Malignancies Detected in Some Patients Treated With bluebird bio’s Active Cerebral Adrenoleukodystrophy Gene Therapy Eli-Cel

Hematological Malignancies Detected in Some Patients Treated With bluebird bio’s Active Cerebral Adrenoleukodystrophy Gene Therapy Eli-Cel

Noah Stansfield
October 15th 2024
Article

Seven of 67 patients treated with eli-cel across multiple clinical trials have developed hematologic malignancies, according to findings published in The New England Journal of Medicine.

© 2024 MJH Life Sciences

All rights reserved.